Precision Medicine for Pediatric Glioma and NF1-Associated Tumors: The Role of Small Molecule Inhibitors

Precision Medicine for Pediatric Glioma and NF1-Associated Tumors: The Role of Small Molecule Inhibitors

Pediatric gliomas encompass the most common brain tumor in children and are subdivided into pediatric low-grade gliomas (pLGGs) and pediatric high-grade gliomas (pHGGs). The era of molecular diagnosis has shifted the treatment paradigms and management of these patients. RAS/MAPK pathway alterations...

Full description

Saved in:

Bibliographic Details
Main Authors:	Samuele Renzi, Julie Bennett, Nirav Thacker, Chantel Cacciotti
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Current Oncology
Subjects:	glioma MEK inhibitor BRAF inhibitor Pan-RAF inhibitor FGFR inhibitor TRK inhibitor
Online Access:	https://www.mdpi.com/1718-7729/32/5/280
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review
by: Nina Yu, et al.
Published: (2024-12-01)

Comparison of the efficacy of rechallenge with anti-PD-1 antibody monotherapy and BRAF/MEK inhibitor in advanced malignant melanoma: A single-center, retrospective cohort study
by: Ken Horisaki, et al.
Published: (2025-04-01)

The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies
by: Saber Imani, et al.
Published: (2024-11-01)

Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
by: Eunyoung Tak, et al.
Published: (2025-03-01)

The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis
by: Mohammad Amin Habibi, et al.
Published: (2025-06-01)

Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim–Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report
by: Yuto Hibino, et al.
Published: (2024-12-01)

Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study
by: Malte Beckmann, et al.
Published: (2024-11-01)

Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer
by: Tobias Max Philipp Hartwich, et al.
Published: (2024-09-01)

Three locally invasive infantile fibrosarcoma cases treated with larotrectinib
by: Hikmet Gülşah Tanyıldız, et al.
Published: (2025-02-01)

MEK inhibitors for the treatment of immunotherapy-resistant, AGK-BRAF fusion advanced acral melanoma: a case report and literature review
by: Yanling Zhang, et al.
Published: (2025-04-01)

MED12 mutation induces RTK inhibitor resistance in NSCLC via MEK/ERK pathway activation by inflammatory cytokines
by: Hyun-Min Ryu, et al.
Published: (2025-08-01)

Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma
by: S. K. Zyryanov, et al.
Published: (2024-02-01)

Two Cysteines in Raf Kinase Inhibitor Protein Make Differential Contributions to Structural Dynamics In Vitro
by: Hyun Sang Cho, et al.
Published: (2025-01-01)

Review of Small Molecule Anticancer NF-κB Inhibitors
by: Sh. R. Kzyrgalin, et al.
Published: (2023-07-01)

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state
by: Mohammad Fallahi‐Sichani, et al.
Published: (2017-01-01)

Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c‐Jun pathway in adaptive resistance to drug‐induced apoptosis
by: Mohammad Fallahi‐Sichani, et al.
Published: (2015-03-01)

Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR
by: Jinhao Chen, et al.
Published: (2025-03-01)

NTRK fusion promotes tumor migration and invasion through epithelial–mesenchymal transition and closely interacts with ECM1 and NOVA1
by: Siqing Zeng, et al.
Published: (2024-12-01)

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma
by: Vivian Chua, et al.
Published: (2019-01-01)

Small molecule inhibitors targeting the cancers
by: Gui‐Hong Liu, et al.
Published: (2022-12-01)

Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report
by: Hannah Haile, et al.
Published: (2025-01-01)

Integrative Multi‐Omics Approaches Reveal Selectivity Profiles and Molecular Mechanisms of FIIN‐2, a Covalent FGFR Inhibitor
by: Ying Fu, et al.
Published: (2025-04-01)

Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations
by: J. Ros, et al.
Published: (2025-09-01)

Navigating Glioma Complexity: The Role of Abnormal Signaling Pathways in Shaping Future Therapies
by: Qiang Chen, et al.
Published: (2025-03-01)

A Successful Case of Vemurafenib and Rituximab for Relapsed Hairy Cell Leukemia
by: QIU Yuchong, et al.
Published: (2025-01-01)

Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma
by: Marloes Faut, et al.
Published: (2018-06-01)

Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma
by: Erin E. Crotty, et al.
Published: (2025-02-01)

Advancing Ocular Safety Profile Assessment: A Novel Grading Scale for Ocular Adverse Reactions Associated with Bemarituzumab
by: Asim V. Farooq, et al.
Published: (2025-05-01)

Sructural rearrangements of NTRK genes: characteristics, methods of detection and targeted therapy for cancer
by: A. A. Kechin, et al.
Published: (2022-01-01)

Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma
by: Katherine J. Crawford, et al.
Published: (2025-07-01)

Specific inhibition of fibroblast growth factor receptor 1 signaling by a DNA aptamer
by: Vladimira Zlinska, et al.
Published: (2025-03-01)

Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies
by: Qiong Sun, et al.
Published: (2025-08-01)

The role of TNF-α inhibitor in glioma virotherapy: A mathematical model
by: Elzbieta Ratajczyk, et al.
Published: (2016-12-01)

Contemporary Patterns of Care for Low-Grade Glioma in Australia and New Zealand
by: Meghana Maddula, et al.
Published: (2025-03-01)

Investigating therapeutic efficacy of dacarbazine and temozolomide, alone and in combination with BRAF(V600E) siRNA in A375 human melanoma cell line
by: Fatemeh Tabandeh, et al.
Published: (2025-06-01)

α-Heteroarylthiomethyl ketones: Small molecule inhibitors of 3CLpro
by: Knez Damijan, et al.
Published: (2025-06-01)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
by: Alireza Azimi, et al.
Published: (2018-03-01)

The role and action mechanism of inhibitors in solutions for etching steel
by: Bosiljka Ljubičić, et al.
Published: (2015-12-01)

α-Glucosidase, Angiotensin-converting Enzyme, and Acetylcholinesterase Inhibitory Activities of a Marine Red Alga Galaxaura oblongata
by: Kimnard Joseph Magsacay Duat, et al.
Published: (2023-09-01)

Targeting WEE1 and asciminib suppresses ABL-tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells
by: Seiichi Okabe, et al.
Published: (2025-07-01)